top
Please input keywords
포스터 다운로드
AACR 2024: Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses
Immune checkpoint blockade therapy (ICT) is effective against tumors, but resistance due to regulatory T cell (Treg) infiltration poses challenges. Targeting CCR8, predominantly expressed on tumor Tregs, with human antibodies offers a promising therapeutic approach. Three fully human monoclonal antibodies targeting CCR8 were developed and characterized in CCR8 knock-out RenMabTM mice. These antibodies recognize a unique epitope, bind to both human and mouse CCR8 proteins, inhibit calcium flux induced by CCL1, and demonstrate potent anti-tumor activity in vivo. These findings suggest that these antibodies are promising candidates for further drug development.
*Name
*Email
*Telephone
*Company
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*City